Xiangjiao Meng

机构：Shandong University, Shandong Tumor Hospital, Shandong First Medical University

发表论文 12 篇 · 总被引 200 次 · h-index 5

代表论文

• Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study (2024 · Journal of Thoracic Oncology · 被引 51)
• Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials (2025 · Nature Medicine · 被引 47)
• Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial (2024 · The Lancet Respiratory Medicine · 被引 42)
• Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study. (2025 · Journal of Clinical Oncology · 被引 10)
• Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancer (2025 · Cancer Letters · 被引 3)
• Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study (2025 · BMC Cancer · 被引 2)